Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial.

Martínez, Enrique; Martínez, Maite; Rico, Mikel; Hernández, Berta; Casas, Francesc; Viñolas, Nuria; Pérez-Casas, Ana; Dómine, Manuel; Mínguez, Julián

Martínez, Enrique; Martínez, Maite; Rico, Mikel; Hernández, Berta; Casas, Francesc; Viñolas, Nuria; Pérez-Casas, Ana; Dómine, Manuel; Mínguez, Julián.

Afiliação

Martínez E; Radiation Oncology Services, Hospital of Navarra, Pamplona, Spain.
Martínez M; Radiation Oncology Services, Hospital of Navarra, Pamplona, Spain.
Rico M; Radiation Oncology Services, Hospital of Navarra, Pamplona, Spain.
Hernández B; Radiation Oncology Services, Hospital of Navarra, Pamplona, Spain.
Casas F; Medical Oncology Department, Clinical Hospital of Barcelona, Barcelona, Spain.
Viñolas N; Medical Oncology Department, Clinical Hospital of Barcelona, Barcelona, Spain.
Pérez-Casas A; Department of Radiation Oncology, Jiménez Díaz Foundation, Madrid, Spain.
Dómine M; Department of Radiation Oncology, Jiménez Díaz Foundation, Madrid, Spain.
Mínguez J; Department of Radiation Oncology, University Hospital of Donostia, San Sebastian, Spain.

Onco Targets Ther ; 9: 1057-66, 2016.

Article em En | MEDLINE | ID: mdl-27042098

Palavras-chave

concurrent; erlotinib; non-small-cell lung cancer; radiotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article